Bylvay access in Lebanon: the MoPH-PDD named-patient pathway
How patients in the Lebanese Republic legally obtain Bylvay (odevixibat) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.
Quick orientation
Patients in Lebanon access Bylvay (odevixibat) for pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC) and pruritus in patients 12 months of age and older with Alagille syndrome through the MoPH-PDD named-patient pathway, a the Pharmacy and Drug Department of the Lebanese Ministry of Public Health-administered mechanism that allows a Lebanese-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in USD.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Reserved for you.
Why Lebanese patients need Bylvay through the named-patient pathway
The Lebanese Republic operates a structured pharmaceutical regulatory environment. Bylvay (odevixibat) is regulated through MoPH-PDD (the Pharmacy and Drug Department of the Lebanese Ministry of Public Health) channels, and a Lebanese family asking for Bylvay is rarely asking for a medicine that does not exist locally. They are usually asking for a precise version of it that the local market has not caught up to.
Four converging patterns drive these cases. First, indication lag. Bylvay's newer FDA-approved indications and dosing expansions often reach local registration 12 to 36 months after the US label. A family whose treating physician has documented a clear FDA-label fit may still find that the local label has not caught up. Second, presentation gaps. The exact strength, weight-banded dose, or pen format the prescriber needs may not be stocked at the local agent even when the medicine is registered. Third, payer denial. out-of-pocket cash (fresh USD) payment, with limited NSSF (CNSS) coverage for chronic conditions and partial reimbursement under Bankers Assurance, MEDIS, and Allianz SNA private health plans each assess specialty therapies case by case, and step-therapy or formulary rules often produce denials even when the drug is on the local register. Cash-pay families pursue cross-border supply rather than wait through appeals. Fourth, continuity of supply. When a US-stable patient relocates to Lebanon or visits family for an extended period, maintaining the original FDA-sourced regimen matters more than switching to a different local presentation.
In each pattern, the MoPH-PDD named-patient pathway is the mechanism that connects a Lebanese-licensed physician's clinical decision with US-sourced, FDA-labeled product for a specific patient. Clinically, Bylvay is a minimally absorbed ileal bile-acid transporter (IBAT, also known as ASBT) inhibitor that reduces enterohepatic recirculation of bile acids, lowering serum bile acid levels and relieving cholestatic pruritus, and the named-patient route preserves that mechanism rather than substituting a non-equivalent local option.
Current regulatory status of Bylvay in Lebanon
The Lebanese Ministry of Public Health - Directorate of Pharmacy (وزارة الصحة العامة - مديرية الصيدلة; MOPH) is the national medicines regulator under Lebanese Pharmacy Profession Law No. 367/1994. Bylvay (odevixibat; Ipsen) is a minimally absorbed ileal bile-acid transporter (IBAT / ASBT) inhibitor for pruritus in paediatric progressive familial intrahepatic cholestasis (PFIC, from 3 months of age) and Alagille syndrome (from 12 months of age). As of 2026-05-31, no public MOPH record of a Lebanon marketing authorisation for odevixibat has been observed on the MOPH registered drugs list.
Access for a Lebanese paediatric PFIC or Alagille patient therefore proceeds through the MOPH Directorate of Pharmacy as a named-patient / compassionate-use import file, typically routed through a hospital pharmacy at AUBMC (Children's Cancer Center of Lebanon hosts the paediatric-hepatology MDT) or Hotel-Dieu de France hospital pharmacy, with an authorised Lebanese pharmaceutical distributor handling the importation under the per-patient permit.
The file specifies the genetic confirmation of PFIC (BSEP / FIC1 / MDR3 variant) or the JAG1 / NOTCH2 variant for Alagille syndrome; baseline serum bile acid level; pruritus severity (Itch Reported Outcome - ItchRO score or equivalent paediatric instrument); prior anti-pruritus therapy history including ursodeoxycholic acid, cholestyramine, rifampicin, and naltrexone; and the weight-banded daily oral dose (40 micrograms/kg, capped at 120 micrograms/kg/day or 6000 micrograms/day, whichever lower).
Last verified by ARCH-74: 2026-05-31. Patient-organisation reporting describes variable processing times tied to post-2019 fiscal-crisis-related currency-control constraints.
Named tertiary centres in Lebanon where Bylvay is dispensed
Odevixibat is a paediatric hepatology product. Lebanese centres equipped for PFIC and Alagille care:
- American University of Beirut Medical Center (AUBMC), Beirut - Department of Paediatrics, paediatric hepatology service. AUBMC also hosts genetic-diagnostic capability for the PFIC variants. Source: AUBMC.
- Children's Cancer Center of Lebanon (CCCL) at AUBMC, Beirut - paediatric specialty centre primarily for haemato-oncology but cross-referrals from paediatric hepatology are routine when transplant planning is on the table. Source: CCCL.
- Hotel-Dieu de France de Beyrouth (USJ), Beirut - paediatric service and hepato-biliary surgery; principal tertiary paediatric centre in the francophone academic network.
- Saint George Hospital University Medical Center, Beirut - paediatric service.
- Hopital Libanais Geitaoui, Beirut - paediatric tertiary.
For complex PFIC and Alagille cases the cross-referral pattern toward AUBMC paediatric hepatology is the most established; transplant pre-assessment in PFIC is referred to AUBMC's adult-paediatric liver-transplant programme.
Local pricing reference for Bylvay in Lebanon
US WAC reference for Bylvay (odevixibat, 200 / 400 / 600 / 1200 microgram oral capsules) is in the order of USD 30,000 to USD 35,000 per 30-day supply at the FDA-labelled weight-banded daily dose for a typical PFIC paediatric patient. The annual reference is correspondingly in the order of USD 360,000 to USD 420,000. Source: Bylvay FDA Prescribing Information.
Post-2019 Lebanon operates a multi-rate currency environment with specialty medicines priced predominantly in fresh USD; the Lebanese Pound has been devalued and pegged at multiple operating rates. We quote Bylvay in USD throughout; an LBP conversion at the day-of-quote operative rate can be issued on request but is not the reference. Source: MOPH.
Price snapshot date: 2026-05-31. Concomitant therapies (ursodeoxycholic acid, fat-soluble vitamins ADEK, monitoring laboratory tests) are locally sourced and represent a separate cost line not part of the import file.
Country-specific access barriers for Bylvay in Lebanon
The principal barrier to Bylvay access in Lebanon is funding, not procedural. The post-2019 fiscal crisis has materially constrained the MOPH Pharmaceutical Aid Programme's capacity to fund high-cost paediatric rare-disease therapies; programme parameters have shifted multiple times since the crisis. For a paediatric PFIC family without private insurance, the principal funding pattern is patient self-pay (in USD), combined with charitable hospital programmes at AUBMC and Hotel-Dieu, supplemented by Ipsen's regional patient-access programme where Lebanon is included.
The National Social Security Fund (NSSF / CNSS) provides health insurance for private-sector employees but specialty-drug coverage of unregistered named-patient imports is subject to formulary exclusion; coverage of odevixibat is policy-specific and customarily requires advance pre-authorisation that often fails for novel rare-disease therapies. Source: CNSS.
Private insurance penetration is variable; insurers including MEDGulf, Bankers Insurance, AROPE, Allianz SNA, and AXA Middle East operate. Paediatric rare-disease coverage tightened materially with USD-denominated pricing pressure during the crisis; current-policy coverage requires direct policy review. For Syrian and Palestinian refugee paediatric patients UNHCR and UNRWA operate parallel referral pathways; rare-disease referrals out of Lebanon to AUBMC and Hotel-Dieu route through these channels where appropriate.
The drug is ambient-storage; customs handling is routine. The binding constraint is upstream supplier availability of odevixibat for export to Lebanon and the financial-clearance pathway for the USD-denominated invoice. Each MOPH permit covers a defined supply window; chronic continuous therapy requires permit renewal per cycle.
Recent local regulatory news touching Bylvay or its drug class in Lebanon
No MOPH bulletin specifically naming odevixibat or the IBAT-inhibitor class has been observed in the last twelve months on the MOPH news and circulars page as of 2026-05-31. Adjacent context:
- MOPH continues iterative communications on the Pharmaceutical Aid Programme's parameters under post-crisis fiscal constraints; specialty-drug-aid eligibility shifts have occurred several times over 2024-2025-2026. Source: MOPH.
- FDA labelling iteration on Bylvay continues to add indications (the Alagille indication was added after the initial PFIC approval); regional regulator engagement typically lags US updates. Source: FDA Drugs@FDA database.
What your physician needs to provide
For a Lebanese-licensed specialist prescribing Bylvay through the MoPH-PDD pathway, the clinical justification letter is the cornerstone of the application. The letter typically documents the patient's confirmed diagnosis for pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC) and pruritus in patients 12 months of age and older with Alagille syndrome, severity assessment (scoring instrument, biomarker, imaging, or biopsy as appropriate for the indication), prior therapy history including first-line options tried, and a clinical rationale for why Bylvay is the appropriate next step given a minimally absorbed ileal bile-acid transporter (IBAT, also known as ASBT) inhibitor that reduces enterohepatic recirculation of bile acids, lowering serum bile acid levels and relieving cholestatic pruritus.
The letter also specifies the exact dosing plan per the FDA-approved label: starting dose, maintenance dose, route of administration, schedule, and intended duration of therapy. Monitoring plan should reference any baseline laboratory or imaging requirements specific to Bylvay (full blood count, liver function, infection screen, ophthalmology assessment, or pregnancy testing where the FDA label requires it), planned follow-up intervals, and dose-modification criteria for the most common adverse events.
The treating physician's Lebanese license number, the dispensing facility license number, and the pharmacy in charge of dispensing complete the package. For cold-chain or specialty-handling products, the dispensing pharmacy's documented storage protocol and continuous-temperature-monitoring log are part of the chain-of-custody record we share with the importer.
Common questions about Bylvay in Lebanon
Will out-of-pocket cash (fresh USD) payment, with limited NSSF (CNSS) coverage for chronic conditions and partial reimbursement under Bankers Assurance, MEDIS, and Allianz SNA private health plans cover this? Each insurer assesses named-patient imports case by case. Some reimburse fully when Bylvay is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.
Is the FDA-approved indication recognised by MoPH-PDD? The MoPH-PDD named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; MoPH-PDD review focuses on the clinical justification rather than re-litigating the FDA decision.
My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine? Any Lebanese-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. The Lebanese Order of Physicians (Beirut or Tripoli branch) and the MoPH Pharmacy and Drug Department verifies the active license; the MoPH-PDD application records both the prescribing physician and the dispensing facility.
Can I receive Bylvay at home? The dispensing facility must be Lebanese-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.
What about competitors or alternative therapies in the same class? Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.
Where Reserve Meds fits in Bylvay cases
Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace MoPH-PDD, and we do not replace your dispensing pharmacy. For Bylvay specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Lebanon, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.
Operationally, a typical Bylvay case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the MoPH-PDD application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.
Lebanese tertiary specialty care concentrates at AUBMC, Hotel-Dieu de France, LAU Medical Center-Rizk Hospital, Clemenceau Medical Center, and Mount Lebanon Hospital in Beirut and Hazmieh; following the post-2019 currency crisis, specialty-medicine pricing is quoted predominantly in fresh US dollars, and the MoPH Pharmacy and Drug Department named-patient import authorisation is the standard mechanism for unregistered specialty medicines.
Next step
If your Lebanese physician has prescribed Bylvay and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.